Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $1.93 Consensus PT from Analysts
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to […]
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to […]
